IMO-2125 Advances to Phase 2 Clinical Trial in PD-1 Refractory Melanoma

Source: Globe News Wire, May 2017

CAMBRIDGE, Mass. and EXTON, Pa., May 04, 2017 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today reported its financial and operational results for the first quarter ended March 31, 2017.

Since January 1, 2017, the Company:

• Completed enrollment in the dose escalation cohorts of the ipilimumab combination arm of the ongoing Phase 1/2 clinical trial of intratumoral IMO-2125 in PD-1 refractory metastatic melanoma;

• No dose-limiting toxicity reported  in studied dose levels; MTD not reached; and
• Durable responses of over a year have been observed;